BURY MICHAEL JONATHAN,CASILLAS LINDA N.,CHARNLEY ADAM KENNETH,DEMARTINO MICHAEL P.,DONG XIAOYANG,EIDAM PATRICK M.,HAILE PAMELA A.,MARQUIS ROBERT W. JR.,RAMANJULU JOSHI M.,ROMANO JOSEPH J.,SINGHAUS ROB
申请号：
NZ62131412
公开号：
NZ621314A
申请日:
2012.08.17
申请国别(地区):
NZ
年份:
2016
代理人:
摘要：
Disclosed herein are 4-amino quinazoline compounds of Formula I wherein the substituents are as defined herein, and methods of making and using the same. The compounds are intended for use as RIP2 Kinase inhibitors and therefore in the treatment of conditions including dermatitis, arthritis, diabetes, ulcerative colitis and Crohn&rsquo；s disease. Specific examples of the compounds of formula I include: N-1,3-benzothiazol-5-yl-6-[(1,1-dimethylethyl)sulfonyl]-4-quinazolinamine and 2-((4-(benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethanol.
